Cargando…

GSTM3 A/B Polymorphism and Risk for Head and Neck Cancer: A Meta-Analysis

BACKGROUND: Glutathione S-transferase M3 (GSTM3) is an important member of the GSTs that plays a critical role in the development of head and neck cancer (HNC). Several studies have investigated between the GSTM3 A/B polymorphism and risk of HNC, however, the results remain controversial. The aim of...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yu, Wang, Jun, Dong, Weiguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3885523/
https://www.ncbi.nlm.nih.gov/pubmed/24416175
http://dx.doi.org/10.1371/journal.pone.0083851
_version_ 1782298757388304384
author Xu, Yu
Wang, Jun
Dong, Weiguo
author_facet Xu, Yu
Wang, Jun
Dong, Weiguo
author_sort Xu, Yu
collection PubMed
description BACKGROUND: Glutathione S-transferase M3 (GSTM3) is an important member of the GSTs that plays a critical role in the development of head and neck cancer (HNC). Several studies have investigated between the GSTM3 A/B polymorphism and risk of HNC, however, the results remain controversial. The aim of this meta-analysis is to evaluate the association between the GSTM3 A/B polymorphism and the risk of HNC. METHODS: All eligible case-control studies published up to July 2013 were identified by searching PubMed and Web of Science. The HNC risk associated with the GSTM3 A/B polymorphism was estimated for each study by odds ratios (OR) together with its 95% confidence interval (CI), respectively. RESULTS: Fourteen studies from ten publications with 2110 patients and 2259 controls were included. Overall, the GSTM3 A/B polymorphism was associated with a decreased risk of HNC using the dominant model, homozygote comparison model and heterozygote comparison model (OR = 0.82, 95%CI: 0.71–0.94; OR = 0.67, 95%CI: 0.49–0.94; and OR = 0.84, 95%CI: 0.73–0.97, respectively); besides, in stratification analyses by ethnicity, similar results were observed in Caucasian populations. Stratification by tumor site indicated that the GSTM3 polymorphism was associated with a decreased risk of laryngeal cancer under recessive model and homozygote comparison (OR = 0.52, 95%CI: 0.30–0.89; and OR = 0.50, 95%CI: 0.29–0.87, respectively); By stratifying source of control, decreased cancer risk was observed in hospital-based population under all genetic models (OR = 0.67, 95%CI: 0.56–0.81 for the dominant model; OR = 0.66, 95%CI: 0.46–0.95 for the recessive model; OR = 0.55, 95%CI: 0.37–0.83 for the homozygote comparison model, and OR = 0.70, 95%CI: 0.58–0.84 for the heterozygote comparison model). CONCLUSIONS: This meta-analysis suggests that the GSTM3 A/B polymorphism may be an important protective factor for HNC, especially of laryngeal cancer and Caucasian populations.
format Online
Article
Text
id pubmed-3885523
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38855232014-01-10 GSTM3 A/B Polymorphism and Risk for Head and Neck Cancer: A Meta-Analysis Xu, Yu Wang, Jun Dong, Weiguo PLoS One Research Article BACKGROUND: Glutathione S-transferase M3 (GSTM3) is an important member of the GSTs that plays a critical role in the development of head and neck cancer (HNC). Several studies have investigated between the GSTM3 A/B polymorphism and risk of HNC, however, the results remain controversial. The aim of this meta-analysis is to evaluate the association between the GSTM3 A/B polymorphism and the risk of HNC. METHODS: All eligible case-control studies published up to July 2013 were identified by searching PubMed and Web of Science. The HNC risk associated with the GSTM3 A/B polymorphism was estimated for each study by odds ratios (OR) together with its 95% confidence interval (CI), respectively. RESULTS: Fourteen studies from ten publications with 2110 patients and 2259 controls were included. Overall, the GSTM3 A/B polymorphism was associated with a decreased risk of HNC using the dominant model, homozygote comparison model and heterozygote comparison model (OR = 0.82, 95%CI: 0.71–0.94; OR = 0.67, 95%CI: 0.49–0.94; and OR = 0.84, 95%CI: 0.73–0.97, respectively); besides, in stratification analyses by ethnicity, similar results were observed in Caucasian populations. Stratification by tumor site indicated that the GSTM3 polymorphism was associated with a decreased risk of laryngeal cancer under recessive model and homozygote comparison (OR = 0.52, 95%CI: 0.30–0.89; and OR = 0.50, 95%CI: 0.29–0.87, respectively); By stratifying source of control, decreased cancer risk was observed in hospital-based population under all genetic models (OR = 0.67, 95%CI: 0.56–0.81 for the dominant model; OR = 0.66, 95%CI: 0.46–0.95 for the recessive model; OR = 0.55, 95%CI: 0.37–0.83 for the homozygote comparison model, and OR = 0.70, 95%CI: 0.58–0.84 for the heterozygote comparison model). CONCLUSIONS: This meta-analysis suggests that the GSTM3 A/B polymorphism may be an important protective factor for HNC, especially of laryngeal cancer and Caucasian populations. Public Library of Science 2014-01-08 /pmc/articles/PMC3885523/ /pubmed/24416175 http://dx.doi.org/10.1371/journal.pone.0083851 Text en © 2014 Xu et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Xu, Yu
Wang, Jun
Dong, Weiguo
GSTM3 A/B Polymorphism and Risk for Head and Neck Cancer: A Meta-Analysis
title GSTM3 A/B Polymorphism and Risk for Head and Neck Cancer: A Meta-Analysis
title_full GSTM3 A/B Polymorphism and Risk for Head and Neck Cancer: A Meta-Analysis
title_fullStr GSTM3 A/B Polymorphism and Risk for Head and Neck Cancer: A Meta-Analysis
title_full_unstemmed GSTM3 A/B Polymorphism and Risk for Head and Neck Cancer: A Meta-Analysis
title_short GSTM3 A/B Polymorphism and Risk for Head and Neck Cancer: A Meta-Analysis
title_sort gstm3 a/b polymorphism and risk for head and neck cancer: a meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3885523/
https://www.ncbi.nlm.nih.gov/pubmed/24416175
http://dx.doi.org/10.1371/journal.pone.0083851
work_keys_str_mv AT xuyu gstm3abpolymorphismandriskforheadandneckcancerametaanalysis
AT wangjun gstm3abpolymorphismandriskforheadandneckcancerametaanalysis
AT dongweiguo gstm3abpolymorphismandriskforheadandneckcancerametaanalysis